Pharmacological Ascorbate for Lung Cancer
brief summary
This clinical trial evaluates adding high-dose ascorbate (vitamin C) to standard of care treatment of non-small cell lung cancer (NSCLC) in adults. All subjects will receive high-dose ascorbate in addition to the standard treatment.
detailed description
Standard treatment for non-small cell lung cancer (NSCLC) involves a combined therapy of paclitaxel and carboplatin. These drugs are administered once every 21 days. This study adds high dose ascorbic acid (75g per infusion) twice per week for up to 4 cycles of therapy.
Participants will:
* receive high doses of intravenous (IV) ascorbate two times a week during each 3 week chemotherapy. * have blood samples drawn to measure blood ascorbate levels once every 21 days * have blood samples drawn to measure iron and ferritin levels before treatment, then on cycles 1 and 3.
The active therapy portion of this study lasts for 4 months. After that is completed, participants will go back to standard therapy for their cancer. Participants will continue to have life-long follow-up for this study.
official title
A Phase II Trial of High-Dose Ascorbate in Stage IV Non-Small Cell Lung Cancer